GBCS · Selectis Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.29M | - | $10.84M | $10.44M | $10.49M | - | $10.02M | $9.58M | $9.49M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $2.13M | - | $2.15M | $2.24M | $2.37M | - | $2.40M | $2.42M | $2.16M | - |
| Total Operating Expenses | $8.55M | - | $11.14M | $10.89M | $10.91M | - | $11.19M | $10.35M | $10.19M | - |
| D&A | $333.2K | - | $364.7K | $409.5K | $363.0K | - | $374.1K | $409.5K | $423.6K | - |
| Operating Income | ($1.26M) | - | ($297.0K) | ($450.3K) | ($421.7K) | - | ($1.17M) | ($763.9K) | ($696.3K) | - |
| Interest Expense | $923.8K | - | $205.7K | $226.0K | $630.3K | - | - | - | - | - |
| Income Tax | $409.7K | - | - | - | - | - | - | - | - | - |
| Net Income | $6.53M | - | $752.4K | ($308.0K) | ($656.0K) | - | ($1.61M) | $794.3K | ($1.03M) | - |
| EPS - Basic | $2.13 | - | $0.24 | ($0.10) | ($0.22) | - | ($0.52) | $0.26 | ($0.34) | - |
| EPS - Diluted | $1.90 | - | $0.24 | ($0.10) | ($0.22) | - | ($0.52) | $0.26 | ($0.34) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.29M | $1.01M | $417.1K | $560.0K | $1.29M | $680.3K | $1.82M | $3.22M | $1.27M | $1.48M |
| Accounts Receivable | $2.49M | $2.28M | $3.19M | $3.04M | $2.88M | $2.62M | $1.90M | $2.19M | $1.83M | $2.09M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $9.82M | $7.58M | $3.96M | $4.00M | $4.75M | $3.53M | $3.53M | $6.00M | $4.20M | $4.96M |
| Total Assets | $30.01M | $32.58M | $33.26M | $33.64M | $34.54M | $33.45M | $33.93M | $36.73M | $39.56M | $40.67M |
| Current Liabilities | $16.32M | $25.27M | $20.30M | $21.23M | $21.52M | $19.63M | $20.20M | $18.26M | $18.15M | $18.15M |
| Long-term Debt | $13.33M | $13.41M | $18.51M | $18.70M | $19.01M | $19.13M | $18.47M | $21.60M | $25.10M | $25.18M |
| Total Liabilities | $29.75M | $38.79M | $38.92M | $40.03M | $40.62M | $38.86M | $38.76M | $39.95M | $43.56M | $43.64M |
| Stockholders' Equity | $258.3K | ($6.21M) | ($5.65M) | ($6.40M) | ($6.08M) | ($5.41M) | ($4.83M) | ($3.22M) | ($4.01M) | ($2.96M) |
| Retained Earnings | ($14.73M) | ($21.24M) | ($20.43M) | ($21.18M) | ($20.86M) | ($20.19M) | ($19.62M) | ($18.00M) | ($18.79M) | ($17.75M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.29M) | - | - | - | $1.04M | - | - | - | $249.5K | - |
| Investing Cash Flow | $5.02M | - | - | - | ($219.2K) | - | - | - | ($116.6K) | - |
| Financing Cash Flow | ($3.11M) | - | - | - | ($182.4K) | - | - | - | ($404.8K) | - |
| CapEx | $377.2K | - | - | - | $219.2K | - | - | - | $116.6K | - |
| Free Cash Flow | ($2.67M) | - | - | - | $816.2K | - | - | - | $132.9K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -17.3% | - | -2.7% | -4.3% | -4.0% | - | -11.7% | -8.0% | -7.3% | - |
| EBITDA margin | -12.7% | - | 0.6% | -0.4% | -0.6% | - | -8.0% | -3.7% | -2.9% | - |
| Net margin | 89.5% | - | 6.9% | -3.0% | -6.3% | - | -16.0% | 8.3% | -10.9% | - |
| Free cash flow margin | -36.6% | - | - | - | 7.8% | - | - | - | 1.4% | - |
| FCF / Net income | -0.41 | - | - | - | -1.24 | - | - | - | -0.13 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 29.2% | - | 19.8% | 21.4% | 22.6% | - | 23.9% | 25.3% | 22.8% | - |
| Effective tax rate | 5.9% | - | - | - | - | - | - | - | - | - |
| Return on assets | 21.7% | - | 2.3% | -0.9% | -1.9% | - | -4.7% | 2.2% | -2.6% | - |
| Return on equity | 2526.2% | - | -13.3% | 4.8% | 10.8% | - | 33.2% | -24.7% | 25.8% | - |
| Return on invested capital | -8.7% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.60 | 0.30 | 0.19 | 0.19 | 0.22 | 0.18 | 0.17 | 0.33 | 0.23 | 0.27 |
| Quick ratio | 0.60 | 0.30 | 0.19 | 0.19 | 0.22 | 0.18 | 0.17 | 0.33 | 0.23 | 0.27 |
| Cash ratio | 0.08 | 0.04 | 0.02 | 0.03 | 0.06 | 0.03 | 0.09 | 0.18 | 0.07 | 0.08 |
| Leverage | ||||||||||
| Debt / Equity | 51.59 | -2.16 | -3.28 | -2.92 | -3.13 | -3.54 | -3.82 | -6.71 | -6.26 | -8.49 |
| Debt / Assets | 0.44 | 0.41 | 0.56 | 0.56 | 0.55 | 0.57 | 0.54 | 0.59 | 0.63 | 0.62 |
| Debt / EBITDA | - | - | 273.29 | - | - | - | - | - | - | - |
| Interest coverage | -1.4x | - | -1.4x | -2.0x | -0.7x | - | - | - | - | - |
| Equity multiplier | 116.17 | -5.25 | -5.89 | -5.26 | -5.68 | -6.18 | -7.02 | -11.41 | -9.87 | -13.72 |
| Liabilities / Assets | 0.99 | 1.19 | 1.17 | 1.19 | 1.18 | 1.16 | 1.14 | 1.09 | 1.10 | 1.07 |
| Efficiency | ||||||||||
| Asset turnover | 0.24 | - | 0.33 | 0.31 | 0.30 | - | 0.30 | 0.26 | 0.24 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 125d | - | 108d | 106d | 100d | - | 69d | 83d | 70d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 2.2x | - | 9.8x | - | - | - | - | 7.7x | - | - |
| P / B | 56.0x | - | - | - | - | - | - | - | - | - |
| P / S | 2.0x | - | 0.7x | 0.6x | 0.6x | - | 0.5x | 0.6x | 0.6x | - |
| EV / EBITDA | - | - | 373.5x | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -30.5% | - | 8.2% | 8.9% | 10.5% | - | 10.7% | 7.3% | -1.2% | - |
| Revenue CAGR (3y) | -8.8% | - | 4.2% | -3.1% | 1.3% | - | 11.0% | 16.8% | 18.1% | - |
| Revenue CAGR (5y) | 4.8% | - | 11.4% | 45.3% | 22.2% | - | 38.2% | 60.4% | 49.4% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -199.3% | - | 74.7% | 41.1% | 39.4% | - | 51.5% | 51.7% | 64.7% | - |
| Net income growth (YoY) | - | - | - | - | 36.6% | - | 29.0% | - | - | - |
| EPS growth (YoY) | - | - | - | - | 35.3% | - | 29.7% | - | - | - |
| EPS CAGR (3y) | 12.9% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | 185.6% | - | 64.4% | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 514.3% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | 30.9% | - | - | - | - | - |
| Book value growth (YoY) | - | -14.8% | -16.9% | -98.7% | -51.8% | -82.5% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$41.44M totalHealth Care$41.38M · 99.8%
Management Fee Revenue$65.8K · 0.2%
Peer comparison
Same SIC group: Real Estate Investment Trusts
Comparing SELECTIS HEALTH against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Jul 20, 2015 | $0.1000 |
| Jul 8, 2015 | $0.1000 |
| Apr 8, 2015 | $0.1000 |
| Dec 4, 2014 | $0.1000 |
| Apr 28, 2014 | $0.1000 |